Book profits in Lupin, hold Sun Pharma: Sriram Rathi

Sriram Rathi of Anand Rathi told CNBC-TV18, "There have been several opportunities in Lupin, which could have drive the earnings surprises, but looking at the current valuations, it seems that that is already into the price and our fair valuation for Lupin is Rs 800 approximately. Possibility of upside from Yasmin, Yaz and other oral contraceptives (OC) products are already into the price. So, we recommend profit booking in Lupin at current valuations."

He further added, "We are recommending to hold on Sun Pharma. We have neutral rating on the stock because there are several triggers which can drive the earning surprise positively. We believe in Sun Pharma 15-20 percent growth could sustain for next two-three years and from currency side also they will be gaining a lot because 75 percent of the revenue is coming in terms of US dollar."